Oxford Cannabinoid Technologies Holdings Plc Logo

Oxford Cannabinoid Technologies Holdings Plc

OCTHF

(0.0)
Stock Price

0,00 USD

-154.68% ROA

-143.95% ROE

-0.51x PER

Market Cap.

3.047.576,00 USD

0% DER

0% Yield

0% NPM

Oxford Cannabinoid Technologies Holdings Plc Stock Analysis

Oxford Cannabinoid Technologies Holdings Plc Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Oxford Cannabinoid Technologies Holdings Plc Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

6 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

7 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Oxford Cannabinoid Technologies Holdings Plc Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Oxford Cannabinoid Technologies Holdings Plc Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Buy
4 Stoch RSI Buy

Oxford Cannabinoid Technologies Holdings Plc Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Oxford Cannabinoid Technologies Holdings Plc Revenue
Year Revenue Growth
2019 0
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Oxford Cannabinoid Technologies Holdings Plc Research and Development Expenses
Year Research and Development Expenses Growth
2019 0
2020 0 0%
2021 633.136 100%
2022 3.965.349 84.03%
2023 5.406.192 26.65%
2024 5.694.044 5.06%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Oxford Cannabinoid Technologies Holdings Plc General and Administrative Expenses
Year General and Administrative Expenses Growth
2019 0
2020 1.382.330 100%
2021 1.518.596 8.97%
2022 0 0%
2023 2.670.151 100%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Oxford Cannabinoid Technologies Holdings Plc EBITDA
Year EBITDA Growth
2019 -1.281.954
2020 -2.248.448 42.98%
2021 -4.009.740 43.93%
2022 -7.467.324 46.3%
2023 -8.763.515 14.79%
2024 -11.631.008 24.65%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Oxford Cannabinoid Technologies Holdings Plc Gross Profit
Year Gross Profit Growth
2019 -1.281.954
2020 -812.591 -57.76%
2021 -234.112 -247.09%
2022 -79.931 -192.89%
2023 -48.750 -63.96%
2024 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Oxford Cannabinoid Technologies Holdings Plc Net Profit
Year Net Profit Growth
2019 -2.616.940
2020 -2.126.217 -23.08%
2021 -4.588.583 53.66%
2022 -6.462.407 29%
2023 -7.468.171 13.47%
2024 -9.716.800 23.14%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Oxford Cannabinoid Technologies Holdings Plc Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2019 0
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Oxford Cannabinoid Technologies Holdings Plc Free Cashflow
Year Free Cashflow Growth
2019 -3.030.010
2020 -1.837.894 -64.86%
2021 -2.463.019 25.38%
2022 -6.754.424 63.53%
2023 -8.627.899 21.71%
2024 -582 -1484908.43%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Oxford Cannabinoid Technologies Holdings Plc Operating Cashflow
Year Operating Cashflow Growth
2019 -2.954.980
2020 -1.537.536 -92.19%
2021 -2.461.926 37.55%
2022 -6.754.424 63.55%
2023 -8.627.899 21.71%
2024 -582 -1484908.43%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Oxford Cannabinoid Technologies Holdings Plc Capital Expenditure
Year Capital Expenditure Growth
2019 75.030
2020 300.358 75.02%
2021 1.093 -27380.15%
2022 0 0%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Oxford Cannabinoid Technologies Holdings Plc Equity
Year Equity Growth
2018 -382.965
2019 1.787.602 121.42%
2020 582.801 -206.73%
2021 20.204.865 97.12%
2022 12.310.815 -64.12%
2023 4.914.038 -150.52%
2024 2.368.470 -107.48%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Oxford Cannabinoid Technologies Holdings Plc Assets
Year Assets Growth
2018 250.006
2019 2.333.304 89.29%
2020 1.327.156 -75.81%
2021 21.623.521 93.86%
2022 14.856.774 -45.55%
2023 5.647.558 -163.07%
2024 3.388.733 -66.66%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Oxford Cannabinoid Technologies Holdings Plc Liabilities
Year Liabilities Growth
2018 632.971
2019 545.702 -15.99%
2020 744.355 26.69%
2021 1.418.656 47.53%
2022 2.545.959 44.28%
2023 733.520 -247.09%
2024 1.020.263 28.1%

Oxford Cannabinoid Technologies Holdings Plc Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.01
Price to Earning Ratio
-0.51x
Price To Sales Ratio
0x
POCF Ratio
-707.96
PFCF Ratio
-802.31
Price to Book Ratio
1.14
EV to Sales
0
EV Over EBITDA
-0.28
EV to Operating CashFlow
-439.71
EV to FreeCashFlow
-439.71
Earnings Yield
-1.95
FreeCashFlow Yield
-0
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0.02
Graham NetNet
0

Income Statement Metrics

Net Income per Share
-0.01
Income Quality
0.9
ROE
-1.44
Return On Assets
-1.55
Return On Capital Employed
-2.55
Net Income per EBT
0.87
EBT Per Ebit
1
Ebit per Revenue
0
Effective Tax Rate
0.13

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-2.22
Return on Tangible Assets
-1.55
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
0
Shareholders Equity per Share
0
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0.23
Current Ratio
3.32
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Oxford Cannabinoid Technologies Holdings Plc Dividends
Year Dividends Growth

Oxford Cannabinoid Technologies Holdings Plc Profile

About Oxford Cannabinoid Technologies Holdings Plc

Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. Its lead drug candidate is OCT461201, a selective CB2 receptor agonist in solid oral dosage form that is in pre-clinical development for use in the treatment of IBS-associated visceral pain, as well as neuropathic pain conditions, including post herpetic neuralgia. The company is also developing OCT130401, which is in pre-clinical development for the treatment of trigeminal neuralgia. Oxford Cannabinoid Technologies Holdings Plc was incorporated in 2017 and is headquartered in London, the United Kingdom.

CEO
Ms. Clarissa Ann Sowemimo-Coke
Employee
7
Address
Maddox House
London, W1S 2PZ

Oxford Cannabinoid Technologies Holdings Plc Executives & BODs

Oxford Cannabinoid Technologies Holdings Plc Executives & BODs
# Name Age
1 Mr. Robin Bennett
General Counsel & Company Secretary
70
2 Ms. Clarissa Ann Sowemimo-Coker
Chief Executive Officer & Executive Director
70
3 Dr. Timothy Henry Corn FFPM, M.Sc.
Executive Director & Chief Medical Officer
70
4 Mr. Indraneil Mahapatra
Co-Founder & Non-Executive Director
70
5 Mr. Paul William Smalley
Finance Director & Executive Director
70
6 Dr. Valentino Parravicini
Chief Scientific Officer
70

Oxford Cannabinoid Technologies Holdings Plc Competitors